August 18, 2026 · Platform news · Galleri (GRAIL)

What happened

The FDA scheduled a public advisory-committee meeting for September 23, 2026 to review the premarket approval application for GRAIL's Galleri multi-cancer early detection blood test. According to GRAIL's own announcement, the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will assess the application GRAIL filed on January 29, 2026. As MedTech Dive notes, this is a milestone review for the field, because no multi-cancer early detection (MCED) test carries FDA approval yet.

The short version

A scheduled advisory panel is a step in a regulatory process, not an approval and not a change to the product a buyer can order today. The decision-relevant fact for a reader is not the meeting date. It is the evidence the panel will weigh: GRAIL's flagship trial has not yet shown a statistically significant drop in late-stage cancer diagnoses, per MedTech Dive. That open question matters more to a screening decision than the calendar.

What it means for you

Galleri is the only blood-based multi-cancer screen among the platforms we benchmark, so its regulatory path is worth watching. But a buyer deciding this month should separate the news from the product. Nothing about how you get Galleri, what it costs, or who can order it changes because a committee has a meeting on the calendar. There is no reason to rush an order ahead of the date, and no reason to wait for it either. The test is available now as a self-pay screen a clinician orders, exactly as it was last week. Our Galleri review carries the current price and ordering routes.

The part that should shape a decision is the evidence base the panel will examine. Galleri is designed to detect a signal shared by more than 50 cancer types from a single blood draw, per MedTech Dive. GRAIL's application rests on large studies: 25,490 consented participants with one year of follow-up in the PATHFINDER 2 study, plus more than 70,000 participants from the intervention arm of the NHS-Galleri trial, according to GRAIL's announcement. Scale like that is unusual for a screening test. Yet MedTech Dive reports that the same landmark trial "failed to demonstrate statistically significant reduction of late-stage cancer diagnoses." For an elective cancer screen, that is the number that counts. Finding a signal earlier only helps if earlier detection changes what happens next, and that link is what the evidence has not yet nailed down.

Adoption is climbing regardless. In the second quarter of 2026, GRAIL sold more than 61,000 Galleri tests, a 35% increase in volume year over year, MedTech Dive reports. Growing use is a market fact, not a verdict on clinical benefit, and the two should not be confused when you are the one paying out of pocket.

How this fits what we already know

In our standing review, Galleri sits in its own category: cancer screening by blood, distinct from the diagnostic panels and the imaging scans elsewhere in the platform lineup. Its defining trade-off has always been that it screens across many cancers at once, several of which have no routine screen today, while the proof that this catches disease early enough to change outcomes is still being built. A favorable panel vote would strengthen its regulatory standing. It would not, on its own, settle the outcomes question the trial data leaves open. We will update the review if the FDA decision lands, expected by the company in the first part of 2027.

Sources

  • GRAIL, "GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri Multi-Cancer Early Detection Test," grail.com (accessed August 18, 2026).
  • MedTech Dive, "FDA sets advisory panel for Galleri multicancer screening test," medtechdive.com (accessed August 18, 2026).

Frequently Asked Questions

Does the FDA panel mean Galleri is now FDA approved?

No. An advisory committee meeting is a public review step, not an approval. The panel votes and advises the FDA, and the agency then makes its own decision later. GRAIL has said it expects a decision in the first part of 2027, per MedTech Dive.

Can I still order Galleri right now?

Yes. Galleri is available today as a self-pay test that a clinician orders. The scheduled September 23, 2026 panel does not change how the test is obtained or what it costs. See our Galleri review for current pricing and the ordering routes.

Did the main Galleri trial show it saves lives?

Not on its primary measure so far. MedTech Dive reported that the flagship three-year trial did not show a statistically significant reduction in late-stage cancer diagnoses. That is a central point for anyone weighing an elective screen, and it is the kind of result the panel exists to examine. A cancer-signal test finds signals; whether earlier detection changes outcomes is a separate, still-open question.

Should Galleri replace my colonoscopy or mammogram?

No. A multi-cancer blood test is designed to layer on top of standard, age-based screening, not to replace it. Colonoscopy, mammography, cervical screening and lung CT remain the standard of care regardless of a blood-test result. Discuss any screening plan with your own clinician.